Browse

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Cited 69 time in Web of Science Cited 75 time in Scopus
Authors
Faivre, S.; Niccoli, P.; Castellano, D.; Valle, J. W.; Hammel, P.; Raoul, J. -L.; Vinik, A.; Van Cutsem, E.; Bang, Yung-Jue; Lee, S. -H.; Borbath, I.; Lombard-Bohas, C.; Metrakos, P.; Smith, D.; Chen, J. -S.; Ruszniewski, P.; Seitz, J. -F.; Patyna, S.; Lu, D. R.; Ishak, K. J.; Raymond, E.
Issue Date
2017-02
Citation
Annals of Oncology, Vol.28 No.2, pp.339-343
Keywords
VEGFR inhibitorantiangiogenicscrossoverrank-preserving structural failure time (RPSFT)blinded independent central review
Abstract
Background: In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 versus 5.5 months; HR, 0.42; P< 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib. Patients and methods: In this randomized, double-blind, placebo-controlled study, cross-sectional imaging from patients was evaluated retrospectively by blinded third-party radiologists using a two-reader, two-time-point lock, followed by a sequential locked-read, batch-mode paradigm. OS was summarized using the Kaplan-Meier method and Cox proportional hazards model. Crossover-adjusted OS effect was derived using rank-preserving structural failure time (RPSFT) analyses. Results: Of 171 randomized patients (sunitinib, n 86; placebo, n 85), 160 (94%) had complete scan sets/time points. By BICR, median (95% confidence interval [CI]) PFS was 12.6 (11.1-20.6) months for sunitinib and 5.8 (3.8-7.2) months for placebo (HR, 0.32; 95% CI 0.18-0.55; P 0.000015). Five years after study closure, median (95% CI) OS was 38.6 (25.6-56.4) months for sunitinib and 29.1 (16.4-36.8) months for placebo (HR, 0.73; 95% CI 0.50-1.06; P 0.094), with 69% of placebo patients having crossed over to sunitinib. RPSFT analysis confirmed an OS benefit for sunitinib. Conclusions: BICR confirmed the doubling of PFS with sunitinib compared with placebo. Although the observed median OS improved by nearly 10 months, the effect estimate did not reach statistical significance, potentially due to crossover from placebo to sunitinib.
ISSN
0923-7534
URI
https://hdl.handle.net/10371/173146
DOI
https://doi.org/10.1093/annonc/mdw561
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse